Absci Corp (NASDAQ:ABSI) — Market Cap & Net Worth
Market Cap & Net Worth: Absci Corp (ABSI)
Absci Corp (NASDAQ:ABSI) has a market capitalization of $1.01 Billion ($1.01 Billion) as of June 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8977 globally and #2498 in its home market, demonstrating a -7.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Absci Corp's stock price $6.80 by its total outstanding shares 155905056 (155.91 Million). Review ABSI total debt and obligations to assess the company's total debt and financial obligations.
Absci Corp Market Cap History: 2021 to 2026
Absci Corp's market capitalization history from 2021 to 2026. Data shows change from $1.28 Billion to $1.06 Billion (-21.03% CAGR).
Index Memberships
Absci Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.04% | #250 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.00% | #949 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.06% | #145 of 263 |
Weight: Absci Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Absci Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Absci Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
194.32x
Absci Corp's market cap is 194.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.28 Billion | $4.78 Million | -$100.96 Million | 267.34x | N/A |
| 2022 | $327.40 Million | $5.75 Million | -$104.90 Million | 56.97x | N/A |
| 2023 | $654.80 Million | $5.72 Million | -$110.57 Million | 114.52x | N/A |
| 2024 | $408.47 Million | $4.53 Million | -$103.11 Million | 90.09x | N/A |
| 2025 | $544.11 Million | $2.80 Million | -$115.18 Million | 194.32x | N/A |
Competitor Companies of ABSI by Market Capitalization
Companies near Absci Corp in the global market cap rankings as of June 15, 2026.
Key companies related to Absci Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Absci Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Absci Corp's market cap moved from $1.28 Billion to $ 1.06 Billion, with a yearly change of -21.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.06 Billion | +94.84% |
| 2025 | $544.11 Million | +33.21% |
| 2024 | $408.47 Million | -37.62% |
| 2023 | $654.80 Million | +100.00% |
| 2022 | $327.40 Million | -74.39% |
| 2021 | $1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Absci Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Billion USD |
| MoneyControl | $1.01 Billion USD |
| MarketWatch | $1.01 Billion USD |
| marketcap.company | $1.01 Billion USD |
| Reuters | $1.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more